Kazmi, S., Sun, L., Moser, J., Alistar, A., Yap, T. A., Garmey, E., . . . Mahalingam, D. Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies. BMJ Publishing Group.
Chicago Style (17th ed.) CitationKazmi, Syed, et al. Phase 1 First-in-human Dose-escalation Study of IMSA101, a Novel Cyclic Di-nucleotide STING Agonist, for Patients with Advanced Solid Tumor Malignancies. BMJ Publishing Group.
MLA (9th ed.) CitationKazmi, Syed, et al. Phase 1 First-in-human Dose-escalation Study of IMSA101, a Novel Cyclic Di-nucleotide STING Agonist, for Patients with Advanced Solid Tumor Malignancies. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.